Table 1.
Experiments (n) | Embryos (n) | 2C arrest (%) | 4–8C arrest (%) | BL (%) | |
---|---|---|---|---|---|
Control | 3 | 218 | 7.38 ± 5.17a | 0.56 ± 0.96j | 88.30 ± 7.23w |
Control‐LNA | 5 | 227 | 10.31 ± 4.59a | 0.32 ± 0.72j | 75.36 ± 2.95w |
LincGET‐LNA1 | 6 | 367 | 86.39 ± 6.72b | 0.00 ± 0.00j | 0.89 ± 1.56x |
LincGET‐LNA2 | 10 | 860 | 90.76 ± 4.28b | 0.00 ± 0.00j | 0.87 ± 1.94x |
LincGET‐LNA3 | 4 | 189 | 76.80 ± 9.72b | 0.00 ± 0.00j | 0.49 ± 0.98x |
Dyei‐LNA | 3 | 149 | 6.39 ± 2.70a | 0.88 ± 1.52j | 77.67 ± 5.81w |
High6248no | 4 | 255 | 8.01 ± 1.55a | 7.78 ± 3.17f | 77.80 ± 4.55w |
LincGET‐LNA2 + High2900no | 3 | 186 | 93.21 ± 1.77b | 0.49 ± 0.84j | 0.00 ± 0.00x |
LincGET‐LNA2 + High2620‐6248 | 3 | 106 | 90.17 ± 3.08b | 1.22 ± 1.28j | 0.00 ± 0.00x |
LincGET‐LNA2 + Low6248no | 3 | 310 | 57.08 ± 4.17c | 11.78 ± 8.49 g | 3.41 ± 1.89y |
LincGET‐LNA2 + High6248no | 4 | 421 | 18.57 ± 1.03d | 50.82 ± 5.76 h | 5.52 ± 3.07z |
Control‐LNA + si‐Egfp | 3 | 74 | 4.06 ± 0.26a | 1.45 ± 2.51j | 79.51 ± 5.37w |
Control‐LNA + si‐Hnrnpu | 3 | 84 | 3.67 ± 0.78a | 2.30 ± 3.98j | 81.21 ± 7.65w |
Control‐LNA + si‐Fubp1 | 3 | 83 | 3.74 ± 0.89a | 0.00 ± 0.00j | 79.69 ± 1.44w |
Control‐LNA + si‐Ilf2 | 3 | 79 | 3.93 ± 0.94a | 2.86 ± 2.58j | 77.37 ± 8.79w |
LincGET‐LNA2 + si‐Egfp | 3 | 106 | 82.29 ± 4.90b | 0.00 ± 0.00j | 0.00 ± 0.00x |
LincGET‐LNA2 + si‐Hnrnpu | 3 | 118 | 85.78 ± 5.25b | 0.76 ± 1.31j | 0.00 ± 0.00x |
LincGET‐LNA2 + si‐Fubp1 | 3 | 108 | 54.04 ± 3.51c | 21.24 ± 2.40i | 12.85 ± 1.30v |
LincGET‐LNA2 + si‐Ilf2 | 3 | 118 | 81.44 ± 3.13b | 5.90 ± 1.23f | 0.00 ± 0.00x |
Control‐LNA + OE‐Egfp | 3 | 79 | 3.04 ± 2.64a | 2.54 ± 2.40j | 81.64 ± 3.77w |
Control‐LNA + OE‐Hnrnpu | 3 | 96 | 6.16 ± 2.88e | 17.88 ± 7.68i | 62.42 ± 6.41u |
Control‐LNA + OE‐Fubp1 | 3 | 84 | 89.05 ± 1.91b | 0.00 ± 0.00j | 0.00 ± 0.00x |
Control‐LNA + OE‐Ilf2 | 3 | 108 | 8.06 ± 4.90e | 18.31 ± 7.27i | 63.16 ± 6.53u |
2C, two‐cell stage; 4–8C, four‐ to eight‐cell stage; BL, blastocyst stage; 6,248no, full‐length LincGET1 lacking LincGET‐LNA2 target site; 2,900no, 1–2,900 nt of LincGET1 lacking LincGET‐LNA2 target site; 2,620–6,248, 2,620–6,248 nt of LincGET1. High, 400 ng/μl; low, 150 ng/μl. si‐, siRNA. OE‐, overexpression. Different letters in same column indicate significant difference (P < 0.001).